Navigation Links
Discovery Labs Prices $14.25 Million Public Offering of Common Stock
Date:5/10/2013

r the solicitation of an offer to buy any securities of Discovery Laboratories, Inc. nor shall there be any sale of the securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Discovery Labs

Discovery Laboratories, Inc. is a specialty biotechnology company focused on advancing a new standard in respiratory critical care.  Discovery Labs' novel proprietary KL4 surfactant technology produces a synthetic, peptide-containing surfactant that is structurally similar to pulmonary surfactant.  Discovery Labs is also developing its proprietary drug delivery technologies to enable efficient delivery of aerosolized KL4 surfactant and other inhaled therapies.  Discovery Labs' strategy is initially focused on neonatology and improving the management of respiratory distress syndrome (RDS) in premature infants.  Discovery Labs believes that its RDS product portfolio has the potential to become the new standard of care for RDS and, over time, significantly expand the current worldwide RDS market.  For more information, please visit the Company's website at www.Discoverylabs.com.

Forward-Looking Statements

To the extent that statements in this press release are not strictly historical, all such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.  These forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from the statements made.  Examples of such risks and uncertainties, including those related to Discovery Labs' securities offering and its development programs, are described in Discovery Labs' filings with the Securities and Exchange Commission including
'/>"/>

SOURCE Discovery Laboratories, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Discovery Labs Reports Third Quarter Financial Results and Progress on Lead Programs
2. Receptos and Ono Establish Collaboration with Focus on Bioactive Lipid Discovery Research
3. Cellular Dynamics Announces Commercial Launch of iCellĀ® Neurons for Neuroscience Drug Discovery
4. Discovery of a dark state could mean a brighter future for solar energy
5. Thomson Reuters Research Forecasts the Onset of the Targeted Drug Discovery Era
6. AnaptysBio Announces New Strategic Antibody Discovery
7. Discovery opens door to low-cost negative refraction, new products and industries
8. Thomson Reuters Cortellis Drives Drug Discovery and Development With Powerful New Web Services
9. Discovery in Nature elucidates immune cells in skin and supports novel vaccine approach
10. AlphaBio Centrix, LLC Announces a New Discovery for Programming Energetic Patches
11. Mars, Incorporated Answers Question: How Does Feeding People and Pets Nurture Science and Discovery? At TEDMED 2012
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/3/2015)... SAN DIEGO , March 3, 2015  Neurocrine ... that Kevin Gorman , President and Chief Executive ... Barclays Global Healthcare Conference in Miami.   ... at 10:15am ET (7:15am PT).  The presentation will be ... at http://www.neurocrine.com .   Listeners are ...
(Date:3/3/2015)... 2015 Adaptive Biotechnologies announced today that ... Board of Director as Chair of the Audit Committee. ... Chad oversees all finance, treasury and accounting functions. Since ... finance, treasury and accounting functions, and led the finance ... 2013, he was named Puget Sound Business Journal,s CFO ...
(Date:3/3/2015)... 03, 2015 Crown Bioscience, Inc., a ... launched a new Life Science division specializing in in ... , The first products released include in vivo ... soon to be released in vivo grade monoclonal antibodies ... expand their life science portfolio with additional antibody products ...
(Date:3/3/2015)... 3, 2015 Fried, Frank, Harris, Shriver & ... has joined the Firm as a partner in ... New York office. Mr. Lewis concentrates ... well as other intellectual property and general litigation. A ... represents both plaintiffs and defendants in a range of ...
Breaking Biology Technology:Adaptive Biotechnologies adds Chad Cohen, Zillow Group CFO, to Board of Directors 2Crown Bioscience Launches Life Science Product Catalog 2Leading Patent Attorney Jeffrey Lewis Joins Fried Frank's Intellectual Property Litigation Practice 2Leading Patent Attorney Jeffrey Lewis Joins Fried Frank's Intellectual Property Litigation Practice 3
... first quarter 2008 stock ... repurchase program, BOSTON, April 30 ... image and information management,solutions, today reported unaudited financial results for the first ... ), Q1 Financial Highlights, Revenue: Total revenues for the ...
... LeMaitre,Vascular, Inc. (Nasdaq: LMAT ), a ... financial results for Q1 2008. Q1 2008,revenues were ... 2007., Q1 2008 revenues increased 5% in ... in its vascular category, while general,surgery revenues decreased ...
... New Step in the Company,s Global Branding Strategy, ... today announced the full integration of its Riedel-de ... May 1, 2008,( http://www.sigma-aldrich.com/rebranding )., "We have ... and,services," said Josef Zihlmann, Global Vice President of ...
Cached Biology Technology:AMICAS Reports Financial Results for the First Quarter Ended March 31, 2008 2AMICAS Reports Financial Results for the First Quarter Ended March 31, 2008 3AMICAS Reports Financial Results for the First Quarter Ended March 31, 2008 4AMICAS Reports Financial Results for the First Quarter Ended March 31, 2008 5AMICAS Reports Financial Results for the First Quarter Ended March 31, 2008 6AMICAS Reports Financial Results for the First Quarter Ended March 31, 2008 7AMICAS Reports Financial Results for the First Quarter Ended March 31, 2008 8AMICAS Reports Financial Results for the First Quarter Ended March 31, 2008 9AMICAS Reports Financial Results for the First Quarter Ended March 31, 2008 10AMICAS Reports Financial Results for the First Quarter Ended March 31, 2008 11LeMaitre Vascular Reports Q1 2008 Revenue of $11.8 Million, a 20% Increase 2LeMaitre Vascular Reports Q1 2008 Revenue of $11.8 Million, a 20% Increase 3LeMaitre Vascular Reports Q1 2008 Revenue of $11.8 Million, a 20% Increase 4LeMaitre Vascular Reports Q1 2008 Revenue of $11.8 Million, a 20% Increase 5LeMaitre Vascular Reports Q1 2008 Revenue of $11.8 Million, a 20% Increase 6LeMaitre Vascular Reports Q1 2008 Revenue of $11.8 Million, a 20% Increase 7LeMaitre Vascular Reports Q1 2008 Revenue of $11.8 Million, a 20% Increase 8LeMaitre Vascular Reports Q1 2008 Revenue of $11.8 Million, a 20% Increase 9LeMaitre Vascular Reports Q1 2008 Revenue of $11.8 Million, a 20% Increase 10LeMaitre Vascular Reports Q1 2008 Revenue of $11.8 Million, a 20% Increase 11Sigma-Aldrich Announces the Integration of Riedel-De Haen Into Core Product Brands 2Sigma-Aldrich Announces the Integration of Riedel-De Haen Into Core Product Brands 3
(Date:2/5/2015)... LA JOLLA, Calif. , Jan. 30, 2015 /PRNewswire/ ... realizes the great power and potential for genomic science ... to aid in disease prevention and treatment.  I was ... a potential new, government-funded precision medicine program. ... on advancing the science of genomics—from the first sequenced ...
(Date:1/22/2015)... Research and Markets ( http://www.researchandmarkets.com/research/4trb7t/biometrics_a ) has announced ... Overview" report to their offering. , ... an individual is who she/he is claiming to be, and ... person,s unique physical characteristics, such as fingerprint, hand or palm ...
(Date:1/22/2015)... - Today, FindBiometrics, the leading source of biometrics industry news, interviews ... design. "When we launched FindBiometrics 12 years ago ... , founder and CEO of FindBiometrics. "Now it,s maturing very ... key players on a very broad scale.  We are known ...
Breaking Biology News(10 mins):J. Craig Venter, Ph.D., Co-Founder and CEO, Human Longevity, Inc. (HLI) Participates in White House Precision Medicine Event 2Biometrics - A Global Market Overview 2Biometrics - A Global Market Overview 3Identity Industry Leading Publication Debuts New Look As Biometrics Hit Mainstream 2
... extend a family should avoid using the cholesterol-lowering drugs ... that women who are pregnant should stop taking statins ... cholesterol is essential for normal fetal development. Indeed, ... in children of pregnant women using statins suggested that ...
... for HIV patients may be the best way of treating hepatitis ... A study of a protein called p7, has revealed that differences ... - known as genotypes - alter the sensitivity of the ... protein assists the spread of HCV around the body ...
... researchers from Penn State University and the University of Chicago ... particular virus, called N4, injects an unusual substance -- an ... bacterial cell. The results, which are published in the ... to improved understanding of the infection strategies used by viruses ...
Cached Biology News:Statin warning for pregnant women 2Leeds research points to new therapy for hepatitis C treatment 2Properties of unusual virus revealed in research 2Properties of unusual virus revealed in research 3
... are designed to rapidly and reliably amplify ... APA Technology. APAgene provides hassle-free, ready-to use ... necessary ingredients are provided in each kit. ... for gap filling, localized cloning of genomic ...
Rabbit polyclonal to Yaf9 ( Abpromise for all tested applications)....
... Bovine Calf Serum; U.S. ... seek an uncompromising quality; Low ... Collected from animals of US ... those who seek an uncompromising ...
...
Biology Products: